title: The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.
authors.affiliation: Centre for the AIDS Program in South Africa, Durban. karims1@ukzn.ac.za
authors.forename: Quarraisha
authors.initials: Q
authors.lastname: Abdool Karim
authors.forename: Salim S
authors.initials: SS
authors.lastname: Abdool Karim
authors.forename: Cheryl
authors.initials: C
authors.lastname: Baxter
authors.forename: Gerald
authors.initials: G
authors.lastname: Friedland
authors.forename: Tanuja
authors.initials: T
authors.lastname: Gengiah
authors.forename: Andrew
authors.initials: A
authors.lastname: Gray
authors.forename: Anneke
authors.initials: A
authors.lastname: Grobler
authors.forename: Kogileum
authors.initials: K
authors.lastname: Naidoo
authors.forename: Nesri
authors.initials: N
authors.lastname: Padayatchi
authors.forename: Wafaa
authors.initials: W
authors.lastname: El-Sadr
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D004359:Drug Therapy, Combination; D006678:HIV; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D013019:South Africa; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents